Recombinant Mouse FABP4 Protein (Cys2-Ala132), His-MYC-tagged

• Cat.No.: FABP4-831M
• Product Overview: Recombinant Mouse FABP4 Protein (NP_077717.1) (Cys2-Ala132) was produced by HEK293 Cells expression system. This protein was expressed with a polyhistidine tag at the N-terminus and a myc tag at the C-terminus.

Specification

• Description: Fatty acid-binding protein, adipocyte, also known as Adipocyte-type fatty acid-binding protein, Fatty acid-binding protein 4, Adipocyte lipid-binding protein, and FABP4, is a cytoplasm protein which belongs to thecalycin superfamily and Fatty-acid binding protein (FABP) family. In familial combined hyperlipidemia (FCHL), FABP4 correlated to body mass index (BMI), waist circumference and homeostasis model assessment (HOMA) index.FABP4 levels were associated with triglyceride-rich lipoproteins. In humans serum FABP4 levels correlate significantly with features of PCOS. It appears to be a determinant of atherogenic dyslipidemia. FABP4 pathway mediates the sebaceous gland hyperplasia in keratinocyte-specific Pten-null mice. FABP4 concentration significantly increased with an increasing of MS features and was strongly correlated with body-mass index, triglycerides, HDL-cholesterol concentrations and blood pressure. Patients in the highest quartile of FABP4 presented a six-fold increased odds ratio for MS and a three-fold increased odds for LD, adjusted by age, sex, body-mass index and the antiretroviral therapy. FABP4 is a strong plasma marker of metabolic disturbances in HIV-infected patients, and therefore, could serve to guide therapeutic intervention in this group of patients.
• Source: HEK293
• Species: Mouse
• Tag: His-MYC
• Predicted N Terminal: His
• Form: Lyophilized from sterile 20 mM Tris, 500 mM NaCl, 20 % glycerol, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Molecular Mass: The recombinant mouse Fabp4 consists of 147 amino acids and predicts a molecular mass of 16.5 kDa.
• Protein length: Cys2-Ala132
• Endotoxin: < 1.0 EU per μg protein as determined by the LAL method.
• Purity: > 95 % as determined by SDS-PAGE.
• Stability: Samples are stable for up to twelve months from date of receipt at -70 centigrade.
• Storage: Store it under sterile conditions at -20 centigrade to -80 centigrade. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 mg/ml. Centrifuge the vial at 4℃ before opening to recover the entire contents.
• Shipping: In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
  Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.

Gene Information

• Gene Name: Fabp4 fatty acid binding protein 4, adipocyte [ Mus musculus ]
• Official Symbol: FABP4
• Synonyms: FABP4; P15; ALBP; AFABP; A-FABP; protein 422; Ap2; Lbpl; 422/aP2; ALBP/Ap2
• Gene ID: 11770
• mRNA Refseq: NM_024406
• Protein Refseq: NP_077717
• UniProt ID: P04117

Reviews

06/05/2021

Unveiling a realm beyond the reaches of research, this wondrous reagent stands as the sacred partner.

07/30/2020

Experimentation surges forward with unrivaled celerity, guided by the efficiency of this remarkable reagent.

10/28/2017

The price of the reagent is relatively low, making it highly cost-effective.

Q&As

How is FABP4 involved in the development and progression of metabolic diseases?

FABP4 is implicated in the development and progression of metabolic diseases due to its influence on lipid metabolism and inflammation. Elevated FABP4 expression is observed in adipose tissue and macrophages in obese individuals. FABP4 promotes lipid accumulation, insulin resistance, and the production of pro-inflammatory cytokines, leading to adipose tissue dysfunction and systemic metabolic abnormalities. Inhibition or genetic depletion of FABP4 has been shown to improve metabolic parameters in animal models, highlighting its potential as a therapeutic target for metabolic diseases.

an FABP4 be used as a biomarker for metabolic disorders?

FABP4 has been investigated as a potential biomarker for metabolic disorders, including obesity and type 2 diabetes. Studies have shown that circulating levels of FABP4 are elevated in individuals with these conditions. Increased FABP4 levels have also been associated with insulin resistance, dyslipidemia, and cardiovascular risk factors. However, further research is needed to validate FABP4 as a reliable biomarker and to determine its clinical utility in the diagnosis, prognosis, and monitoring of metabolic diseases.

How does FABP4 interact with other proteins and signaling pathways?

FABP4 interacts with various proteins and signaling pathways to regulate lipid metabolism and inflammation. For instance, FABP4 interacts with PPARγ, a key transcription factor involved in adipogenesis and lipid metabolism. This interaction influences the expression of genes involved in lipid uptake and storage. FABP4 also interacts with inflammatory signaling pathways, such as NF-κB and JNK, modulating the production of pro-inflammatory cytokines. Understanding the molecular interactions of FABP4 can provide insights into its functional roles and potential targets for therapeutic intervention.

What is the role of genetic variants in FABP4 in metabolic disorders?

Genetic variants in the FABP4 gene have been associated with metabolic disorders. Single nucleotide polymorphisms (SNPs) in the FABP4 gene have been linked to obesity, insulin resistance, and dyslipidemia. These genetic variants may alter FABP4 expression, protein structure, or function, leading to dysregulated lipid metabolism and increased susceptibility to metabolic diseases. Further investigation is needed to elucidate the functional consequences of these genetic variants and their potential as predictive markers for metabolic disorders.

What are the potential therapeutic strategies targeting FABP4?

Various therapeutic strategies targeting FABP4 have been explored. Small molecule inhibitors of FABP4 have shown promising results in preclinical studies, attenuating lipid accumulation, improving insulin sensitivity, and reducing inflammation. Additionally, gene silencing approaches, such as RNA interference, have been investigated to suppress FABP4 expression. Furthermore, modulation of FABP4 activity through natural compounds and lifestyle interventions, such as exercise and dietary modifications, may also hold therapeutic potential. However, more research is required to evaluate the safety and efficacy of these strategies in human subjects.

What is the biological function of FABP4 in cellular processes and metabolism?

FABP4, also known as fatty acid-binding protein 4, plays a crucial role in lipid metabolism and cellular processes. It functions as an intracellular transporter for fatty acids, facilitating their uptake, storage, and utilization. Additionally, FABP4 modulates inflammation, insulin sensitivity, and adipocyte differentiation. Its expression is regulated by various factors such as PPARγ and C/EBPα. FABP4 dysregulation has been associated with metabolic disorders, such as obesity and type 2 diabetes, making it an important target for therapeutic interventions.

How does FABP4 contribute to the pathogenesis of cardiovascular diseases?

FABP4 has been implicated in the pathogenesis of cardiovascular diseases due to its involvement in lipid metabolism, inflammation, and atherosclerosis. Elevated FABP4 levels have been observed in individuals with coronary artery disease, and FABP4 has been shown to promote foam cell formation, a key step in atherosclerotic plaque development. FABP4 also influences vascular endothelial function and thrombosis. Inhibition of FABP4 has demonstrated beneficial effects on atherosclerosis progression and cardiovascular outcomes in experimental models. Further research is needed to fully understand the mechanisms underlying the contribution of FABP4 to cardiovascular diseases.